Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Affymax Once-Monthly ESA Will Target Smaller Dialysis Centers

This article was originally published in The Pink Sheet Daily

Executive Summary

Omontys (peginesatide) launches for chronic kidney disease patients on dialysis, while non-dialysis patients were not included in the labeling due to CV event risk. Pricing negotiations will commence following the March 27 approval.

You may also be interested in...



Affymax Considers Bankruptcy As Omontys Investigation Continues

Affymax cuts staff in order to conserve the little cash it has left in its coffers, which will be needed to pay down debts and continue looking into safety issues surrounding its sole commercial product – an investigation that may never be concluded because the company lacks resources.

Affymax's Peginesatide May Be Tough Sell To ODAC As ESAs Cast Long Showdow

Safety concerns over erythropoiesis-stimulating agents seem to extend to Affymax's peginesatide, and since it lacks an efficacy edges over these drugs in treating anemia due to chronic kidney disease, an approval basis is unclear.

Optum Rx Reveals Humira Biosimilar Plan To ‘Support Advancement" Of The Market

United Health's pharmacy benefit manager outlined plans for early inclusion of up to three biosimilar versions of adalimumab on its formularies in 2023, at parity to the brand.

Topics

Related Companies

Related Deals

Latest News
See All
UsernamePublicRestriction

Register

PS073937

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel